A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →. With Zai Lab (Shanghai) Co., Ltd..
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
190estimated
Sites
122
Countries
Argentina, Austria, Brazil +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-21 | actual | When the study began enrolling |
| Primary completion | 2026-03-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-15 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Carcinoma, Non-Small-Cell Lung
Interventions
- Drug: Repotrectinib — also filed as BMS-986472
- Drug: Crizotinib — also filed as Xalkori
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival (PFS) as per Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
measured Up to approximately 41 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed